- Home
- OSCR vs IBRX Comparison
OSCR vs IBRX Comparison
Compare OSCR & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSCR | IBRX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.2B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OSCR | IBRX |
|---|---|---|
| Price | $32.04 | $8.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $16.88 | $12.57 |
| AVG Volume (30 Days) | 5.5M | ★ 7.2M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $11,701,427,000.00 | $113,288,000.00 |
| Revenue This Year | $63.89 | $88.59 |
| Revenue Next Year | $5.30 | $131.15 |
| P/E Ratio | $10.03 | ★ N/A |
| Revenue Growth | 27.50 | ★ 668.31 |
| 52 Week Low | $10.69 | $1.95 |
| 52 Week High | $33.55 | $12.43 |
Technical Indicators
Market Signals| Indicator | OSCR | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 53.15 |
| Support Level | $27.81 | $7.77 |
| Resistance Level | $32.73 | $8.51 |
| Average True Range (ATR) | 1.66 | 0.35 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 58.14 | 41.29 |
Price Performance
Historical ComparisonAbout OSCR Oscar Health Inc.
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.